JPWO2022202785A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022202785A5
JPWO2022202785A5 JP2023509184A JP2023509184A JPWO2022202785A5 JP WO2022202785 A5 JPWO2022202785 A5 JP WO2022202785A5 JP 2023509184 A JP2023509184 A JP 2023509184A JP 2023509184 A JP2023509184 A JP 2023509184A JP WO2022202785 A5 JPWO2022202785 A5 JP WO2022202785A5
Authority
JP
Japan
Prior art keywords
administration
dosage
pharmaceutical composition
administration method
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023509184A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022202785A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/013074 external-priority patent/WO2022202785A1/ja
Publication of JPWO2022202785A1 publication Critical patent/JPWO2022202785A1/ja
Publication of JPWO2022202785A5 publication Critical patent/JPWO2022202785A5/ja
Pending legal-status Critical Current

Links

JP2023509184A 2021-03-22 2022-03-22 Pending JPWO2022202785A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021047225 2021-03-22
PCT/JP2022/013074 WO2022202785A1 (ja) 2021-03-22 2022-03-22 ポリペプチド並びにそれを含む細胞融合剤及びがん治療用医薬組成物

Publications (2)

Publication Number Publication Date
JPWO2022202785A1 JPWO2022202785A1 (https=) 2022-09-29
JPWO2022202785A5 true JPWO2022202785A5 (https=) 2024-12-16

Family

ID=83397484

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509184A Pending JPWO2022202785A1 (https=) 2021-03-22 2022-03-22

Country Status (3)

Country Link
US (1) US20250129122A1 (https=)
JP (1) JPWO2022202785A1 (https=)
WO (1) WO2022202785A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025225632A1 (ja) * 2024-04-23 2025-10-30 美智子 甲賀 コロナウイルス感染症の治療又は予防用医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861236B2 (en) * 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
AP2081A (en) * 2004-06-18 2010-01-04 Ipf Pharmaceuticals Gmbh Oligomeric peptides and their use for the treatment of HIV infections
AU2006227816B2 (en) * 2005-03-15 2012-04-05 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
WO2008063663A2 (en) * 2006-11-21 2008-05-29 University Of Southern California Poly (ethylene glycol) anti-body detection assays and kits for performing thereof
US20110117171A1 (en) * 2009-11-18 2011-05-19 Affinergy, Inc. Implantable bone graft materials
WO2018098282A2 (en) * 2016-11-22 2018-05-31 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
WO2021054448A1 (ja) * 2019-09-20 2021-03-25 美智子 甲賀 ペプチド並びにそれを含む細胞融合剤及びがん治療用医薬組成物

Similar Documents

Publication Publication Date Title
US4507323A (en) Treatment of psychosexual dysfunctions
EP2799071B1 (en) Levocetirizine and montelukast for the treatment of influenza and common cold
AU2014249534B2 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
JP6196041B2 (ja) 大うつ病を有する患者において減量療法を提供する方法
US20030105121A1 (en) Method of preventing lipodystrophy syndrome or reversing a pre-existing syndrome in HIV-infected patients being treated with antiretroviral agents
US20200101067A1 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
CN111032158A (zh) 用于治疗抑郁的nk-1拮抗剂组合物和方法
CN109316480A (zh) 组合als疗法
JP2024010018A (ja) うつ病を治療するための組成物および方法
US20090149518A1 (en) Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis
JPH0667842B2 (ja) 基本的うつ病を軽減するためのうつ病治療剤
JPWO2022202785A5 (https=)
US20250319067A1 (en) Improved Pharmacokinetics of Tryptamine Prodrugs
EP0171227B1 (en) Use of propiophenone compound
CN118973574A (zh) 异丁司特治疗新冠肺炎后遗症的用途
US20170231987A1 (en) Levosimendan for use in the treatment of motor neuron diseases (e.g. als)
US10071077B2 (en) Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation
PT2877192T (pt) Composições para o tratamento de fadiga relacionada com o cancro
TWI289060B (en) Pharmaceutical composition for improving the recovery of post-stroke patients
Aizenberg et al. Sildenafil for selective serotonin reuptake inhibitor-induced erectile dysfunction in elderly male depressed patients
JP5380930B2 (ja) 睡眠改善剤
IL230174A (en) Pharmaceutical composition for the treatment of premature ejaculation
RU2611383C2 (ru) Комбинированный препарат для устранения симптомов и лечения острых респираторных вирусных инфекций и гриппа
WO2005063253A1 (ja) アレルギー症状治療用医薬組成物
RU2498797C2 (ru) Комбинированное средство для лечения гриппа и орви